GlaxoSmithKline PLC found using ticker (GSK) now have 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 55 and 45.64 calculating the average target price we see 50.32. Now with the previous closing price of 43.75 this would indicate that there is a potential upside of 15.0%. The 50 day MA is 43.11 and the 200 day moving average is 41.7. The company has a market cap of $113,295m. Find out more information at: https://www.gsk.com
The potential market cap would be $130,308m based on the market concensus.
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics; Alector; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences and Vir Biotechnology GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
